Aqupla
(Nedaplatin)Phase 3Small molecule
Jiangsu Simcere Pharmaceutical Co., Ltd.Nedaplatin is a chemotherapy drug used to treat various cancers, particularly ovarian cancer and lung cancer, by stopping cancer cells from growing and dividing.[1] Aqupla is currently being investigated across 9 indications[3], with its most advanced program in Phase 3.[1]
Aqupla is one of 190 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.
9
Indications
28
Total Trials
9
Active Trials
189
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Phase 3
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Rilvegostomig
AstraZenecaPreclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nasopharyngeal Carcinoma6 trials
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
Recruiting·—·Phase 3·NCT04437329·352 enrolled
Show 3 more trials
Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma
Unknown status·—·Phase 2·NCT01265147·20 enrolled
Nedaplatin in Treatment for Nasopharyngeal Carcinoma
Completed·—·Phase 2·NCT04834206·32 enrolled
Esophageal Squamous Cell Carcinoma4 trials
Esophageal Carcinoma3 trials
Lung Cancer1 trial
Salivary Gland Carcinoma1 trial
13 more indications
Neoadjuvant Therapy1 trial
Lymphoma1 trial
Cervical Cancer1 trial
Pelvic External Combined With 252-Cf Neutron Intracavitary Radiotherapy With or Without Platinum in Treating Advanced Cervical Cancer
Unknown status·—·Phase 2·NCT02835404·200 enrolled
Esophageal Cancer1 trial
Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer
Unknown status·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT03649945·186 enrolled
Phase II Clinical Trial1 trial
Breast Cancer1 trial
Capecitabine1 trial
Squamous Cell Carcinoma1 trial
Neoadjuvant Treatment1 trial
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Recruiting·—·Phase 3·NCT06102395·272 enrolled
Esophageal Squamous Cell Cancer1 trial
Squamous Carcinoma1 trial
Esophageal Squamous Carcinoma1 trial
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT07019181·26 enrolled
Head and Neck Squamous Cell Carcinoma1 trial
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
Unknown status·—·Phase 2·NCT06170697·46 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nedaplatin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details